Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nektar Therapeutics
Biotech
Nektar stock doubles as phase 2b eczema trial hits endpoints
The biotech reported a phase 2 win in atopic dermatitis, sending its stock up 119% despite the data falling short of the bar set by Dupixent.
Nick Paul Taylor
Jun 24, 2025 9:20am
J&J vet jumps to Affinia—Chutes & Ladders
Feb 7, 2025 8:30am
Nektar CEO slams Lilly's 'egregious error,' laments lost time
Aug 8, 2023 8:18pm
Nektar accuses Lilly of botching eczema clinical trial analysis
Aug 7, 2023 8:30am
Lilly hands rights to immunology med back to Nektar
Apr 27, 2023 9:14am
Nektar sticks with immunology, lays off 60% of SF workforce
Apr 18, 2023 7:00am
